Brought to you by 
Novartis gets an option to Transgene's TG4010; option not exercised
16 Nov 2021
Executive Summary
Novartis licensed the exclusive option to globally develop and market Transgene SA's (immunotherapies for cancer and infectious disease; part of Institut Merieux) TG4010 (MVAMUC1IL2). The compound is ready to begin Phase IIb/III trials as a first-line treatment for MUCI-positive non-small cell lung cancer (NSCLC) and other types of cancer.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Immuno-Oncology
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis gets an option to Transgene's TG4010; option not exercised
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice